CNXU (Conexeu Sciences) Total Liabilities: $1.00 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNXU Conexeu Sciences Inc CNXU
12 GF Score
Price $7.08
! 1 Warning Sign
View Full Analysis

What is Conexeu Sciences Total Liabilities?

Conexeu Sciences CNXU -12.26% 12 Total Liabilities is $1.00 Mil as of Apr. 2026. GuruFocus rates CNXU with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Conexeu Sciences's Total Liabilities for the quarter that ended in Apr. 2026 was $1.00 Mil.

Conexeu Sciences's quarterly Total Liabilities increased from Oct. 2025 ($0.34 Mil) to Jan. 2026 ($0.88 Mil) and increased from Jan. 2026 ($0.88 Mil) to Apr. 2026 ($1.00 Mil).

Conexeu Sciences's annual Total Liabilities increased from . 20 ($0.00 Mil) to Oct. 2024 ($0.44 Mil) but then declined from Oct. 2024 ($0.44 Mil) to Oct. 2025 ($0.34 Mil).


Conexeu Sciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Conexeu Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Conexeu Sciences Total Liabilities Chart

Conexeu Sciences Annual Data
Trend Oct24 Oct25
Total Liabilities
0.44 0.34

Conexeu Sciences Quarterly Data
Oct24 Jan25 Apr25 Oct25 Jan26 Apr26
Total Liabilities Get a 7-Day Free Trial 0.00 0.00 0.34 0.88 1.00
CNXU
12GF Score
Conexeu Sciences Inc CNXU
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Conexeu Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Conexeu Sciences's Total Liabilities for the fiscal year that ended in Oct. 2025 is calculated as

Total Liabilities=Total Assets (A: Oct. 2025 )-Total Equity (A: Oct. 2025 )
=7.689-7.353
=0.34

Conexeu Sciences's Total Liabilities for the quarter that ended in Apr. 2026 is calculated as

Total Liabilities=Total Assets (Q: Apr. 2026 )-Total Equity (Q: Apr. 2026 )
=8.2-7.196
=1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $1.00 Mil mean?
Conexeu Sciences (CNXU) has a Total Liabilities of $1.00 Mil as of Apr. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Conexeu Sciences and its competitors.
Is Conexeu Sciences' Total Liabilities too high?
Conexeu Sciences' current Total Liabilities is $1.00 Mil. Overall, Conexeu Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Conexeu Sciences' Total Liabilities compare to GALT and SRZN?
Conexeu Sciences' Total Liabilities of $1.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Conexeu Sciences and its competitors. Conexeu Sciences's current Total Liabilities is $1.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Conexeu Sciences stock overvalued right now?
Conexeu Sciences (CNXU) has a current Total Liabilities of $1.00 Mil. The current Total Liabilities is $1.00 Mil. Conexeu Sciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Conexeu Sciences (CNXU), the current Total Liabilities is $1.00 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Conexeu Sciences Business Description

Address 50 West Liberty Street, Suite 880, Reno, NV, USA, 89501
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
12GF Score

Get the complete analysis for CNXU

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.08
Price